Atopic Dermatitis Pipeline Drugs Assessment Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2020-2031 

Atopic dermatitis is a chronic, pruritic inflammatory skin disease with unknown origin. It generally occurs in children but affects a substantial number of adults.Symptoms include dry skin, itching, red to brownish-grey patches especially on hands, neck, upper feet, legs, inside the bend of elbows, knees and other parts of the body. Atopic dermatitis generally examined through the physical examination. No cure has been found for atopic dermatitis, but the treatment is given for relieving the symptoms. Treatment may include topical applications to relieve the itching, oral drugs to control the inflammation and drugs for infection control.Food and Drug Administration (FDA) has recently approved a new, injectable monoclonal antibody, dupilumab for the treatment of severe atopic dermatitis.

 Key Developments:

Currently, there is no availability of effective treatments to treat atopic dermatitis. Most of the drugs are used to relieve the symptoms. Two Janus kinase inhibitors approved for rheumatoid arthritis and myelodysplasia. One of these drugs isstudied for atopic dermatitis but drug is not actively developed now. Many Janus kinase inhibitors are in clinical trial stages for treatment of atopic dermatitis.

• In March 2017, LEO Pharma announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD).
• In January 2017, AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.